Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.67 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438097 | 0.88 | NR4A2 (0.69) | NR4A2ALOX5MEN1KMT2AKDM4E | |
| SCHEMBL14709940 | 0.85 | NR4A2 (0.61) | NR4A2ALOX5MEN1KMT2AKDM4E | |
| SCHEMBL31312750 | 0.85 | TUBB4A (0.62) | NR4A2ALOX5MEN1KMT2AKDM4E | |
| SCHEMBL5621441 | 0.84 | NR4A2 (0.60) | NR4A2ALOX5MEN1KMT2AKDM4E | |
| SCHEMBL6492107 | 0.83 | CCNB2 (0.56) | ALOX5CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5137730 | 0.81 | NR4A2 (1.00) | NR4A2ALOX5MEN1KMT2AKDM4E | |
| SCHEMBL4338589 | 0.81 | ALOX5 (1.00) | NR4A2ALOX5MEN1KMT2AKDM4E | |
| SCHEMBL18180604 | 0.80 | CCNB2 (0.53) | CCNB2CDK1CCNB1CCNB3MEN1 | |
| SCHEMBL31312633 | 0.80 | ALOX5 (0.57) | NR4A2ALOX5 | |
| SCHEMBL26031834 | 0.78 | NR4A2 (0.59) | NR4A2ALOX5MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495541-B1 | POTENTIATION OF ANTICANCER THERAPIES AND INHIBITION OF NEUROTOXICITY CONSEQUENT TO STROKE, HEAD TRAUMA, AND NEURO-DEGENERATIVE DISEASES; SUCH AS 2-BROMO-3,4-DIHYDROPYRROLO-(4,3,2-DE)ISOGUINOLIN-5-ONE | AGOURON PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |